Caption Management’s PDS Biotechnology PDSB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$193K Buy
+319,100
New +$240K ﹤0.01% 1347
2025
Q4
Sell
-219,000
Closed -$221K 1957
2025
Q3
$221K Buy
+219,000
New +$257K ﹤0.01% 1452
2025
Q2
Sell
-45,500
Closed -$54.1K 1791
2025
Q1
$54.1K Buy
45,500
+18,100
+66% +$25.7K ﹤0.01% 1388
2024
Q4
$44.7K Sell
27,400
-72,600
-73% -$192K ﹤0.01% 1371
2024
Q3
$382K Sell
100,000
-19,000
-16% -$63.4K 0.01% 976
2024
Q2
$349K Buy
+119,000
New +$381K 0.01% 870

Other funds holding PDSB

Caption Management's PDSB Position: Q1 2024 in Review

Caption Management sold out of PDS Biotechnology (PDSB) in Q1 2024, closing a stake of 8,181 shares — an estimated $40.7K sold.

Caption Management first reported a position in PDSB in Q4 2023 and held it in 1 quarter. The position peaked at $40.7K in Q4 2023. 72 funds tracked by Wall St. Rank hold PDSB as of Q1 2024.

  • Caption Management reported no remaining PDS Biotechnology position as of Q1 2024 after selling out during the quarter.
  • Caption Management sold 8,181 PDS Biotechnology shares in Q1 2024, an estimated $40.7K.
  • Caption Management first reported a position in PDS Biotechnology in Q4 2023 and held it in 1 quarter.
  • Caption Management's PDS Biotechnology position peaked at $40.7K in Q4 2023.
  • 72 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2024.

Based on Caption Management's 13F filing for Q1 2024, filed 15 May 2024.